Related Experiment Video

Updated: Aug 29, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

[Vaccines against meningococcal disease]

W A Costa1

  • 1Centro de Vigilância Epidemiológica, Secretaria Estadual de Saúde, São Paulo.

Jornal De Pediatria
|March 1, 1995
PubMed

Insights

Meningococcal disease outbreaks are a global concern. Current vaccines protect against serogroups A, C, Y, and W-135 but have limitations, with no effective vaccines available for serogroup B.

Area of Science:

  • Microbiology
  • Epidemiology
  • Vaccinology

Context:

  • Meningococcal disease poses a significant global health threat, with periodic epidemics reported worldwide.
  • Neisseria meningitidis serogroups A, B, and C are the most prevalent and concerning.
  • Existing vaccines target serogroups A, C, Y, and W-135 but have limitations in age range and duration of protection.

Purpose:

  • To review the current landscape of meningococcal vaccines and chemoprophylaxis strategies.
  • To highlight the challenges in developing effective vaccines, particularly against serogroup B.
  • To discuss future perspectives in meningococcal disease prevention.

Summary:

  • Vaccines against meningococcal serogroups A, C, Y, and W-135 are available but not routinely used due to limitations.
  • No consistently effective vaccines exist for serogroup B meningococci, necessitating ongoing research.
  • Chemoprophylaxis for close contacts remains the primary method to prevent secondary cases.

Impact:

  • Emphasizes the need for improved meningococcal vaccines, especially for serogroup B.
  • Underscores the importance of continued epidemiological surveillance for meningococcal disease.
  • Suggests that conjugated vaccine technologies may offer future breakthroughs in prevention.

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Related Concept Videos

Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Vaccinations01:51

Vaccinations

Overview
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...